BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PharmaVigilant Releases I-Warehouse 3.0 for Enhanced Data Storage and Reporting


1/19/2011 9:49:45 AM

WESTBOROUGH, MA--(Marketwire - January 19, 2011) - PharmaVigilant, a clinical trial technology provider, today announced the availability of I-Warehouse 3.0, an enhanced version of the company's unprecedented clinical data warehouse. The state-of-the-art system gives companies an innovative technology solution that provides immediate and ubiquitous access to study data with comparable results.

With I-Warehouse 3.0, the user interface has been redesigned to address the increasingly complex clinical trial environment. New features and functionality now streamline reporting to accommodate even more complex queries across multiple trials, and provides clients with access to their data at their fingertips. I-Warehouse offers superior organization of search criteria and a more streamlined selection process with drag and drop features, pre-populated mathematical calculations, and one-click results in the form of data on demand. Additionally, descriptive graphical summaries render visual components for study data results and report comparisons.

"I-Warehouse 3.0 was specifically redesigned in response to client feedback to provide a more user-friendly system for running reports and tracking study data," says James DeSanti, Founder and CEO, PharmaVigilant. "With this redesign, we are empowering customers to significantly expand their ability to meet the increased regulatory and safety challenges facing the industry. I-Warehouse now offers unprecedented access to all data from trials running on our InSpire EDC solution. This gives our clients even more control and flexibility with their data."

Additional unparalleled features of I-Warehouse 3.0 include:

  • Data on demand
  • Import utility enabling competitive datasets to be incorporated into I-Warehouse
  • Excel and PDF exports
  • Customized charts and graphs
  • Report regeneration
  • Saved search criteria

PharmaVigilant offers a full suite of clinical trial technology offerings including: Electronic Data Capture (InSpire); study building (I-Builder 2.0); Electronic Trial Master File System (I-Vault); Remote Source Document Verification (rSDV); study administration; and an automated site payment system (PaySite). PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 18 countries across North America, South America, and Asia and continues to expand rapidly.

About PharmaVigilant:
Based in Westborough, Mass., PharmaVigilant is a SaaS company founded in 2005 to provide broader technologies to streamline the clinical trial process for biopharmaceutical companies. Its full suite of patient-based technology automates the collection, management and analysis of clinical trial data and most importantly puts that data in the sponsors' hands when and how they want it. Sponsors rely on PharmaVigilant to ease the regulatory and FDA submission and approval process and ultimately go-to market more quickly with top quality drugs. For more information, visit www.pharmavigilant.com.


Contact information:
Jennifer Burns
SHIFT Communications
(617) 779-1809
Jburns@shiftcomm.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES